MGI(SH:688114) Shen Zhen Shang Bao·2025-10-25 12:16Core Insights - BGI Genomics reported a revenue of 1.869 billion yuan for the first nine months of the year, a slight decrease of 0.01% compared to the same period last year [1] - The company incurred a net loss of 120 million yuan for the first nine months, with a non-recurring net loss of 228 million yuan [1] - As of the end of Q3, the net cash flow from operating activities was -289 million yuan [1] Financial Performance - In Q3, BGI Genomics achieved a revenue of 755 million yuan, representing a year-on-year growth of 14.45% [1] - The net loss for Q3 was 16 million yuan, with a non-recurring net loss of 25.39 million yuan [1] - The latest gross margin was 53.32%, down 5.81 percentage points from the same period last year [1] - The latest debt-to-asset ratio was 23.69%, an increase of 4.06 percentage points compared to the same period last year [1] Research and Development - The company reduced its R&D expenditure to 447 million yuan in the first three quarters, a decrease of 24.25% year-on-year [1] - R&D spending accounted for 23.94% of total revenue, down 7.66 percentage points year-on-year [1] - BGI Genomics stated that it is focusing on cost reduction and efficiency improvement, leading to a decrease in R&D investment [1] Ownership Structure - As of September 30, 2025, major shareholders include Shenzhen BGI Technology Holdings Group Co., Ltd. with 36.73% ownership, and other investors with smaller stakes [2] - CPE Investment reduced its stake by 0.59 percentage points in Q3 2025 compared to the previous half-year report [2]